HHS Logo U.S. Department of Health & Human Services Divider arrow NIH logo National Institutes of Health Alt desc
Skip Over Navigation Links
Staff banner

Staff Profile: Madhu Lal-Nag

Madhu A. Lal-Nag, Ph.D.
Madhu A. Lal-Nag, Ph.D.

Lead, Trans-NIH RNAi Facility

Division of Pre-Clinical Innovation

National Center for Advancing Translational Sciences

National Institutes of Health

E-mail Madhu A. Lal-Nag

Biography

Madhu A. Lal-Nag currently serves as the lead of the Trans-NIH RNAi Facility, which is responsible for developing and conducting genome-wide, physiologically relevant phenotypic assays for Intramural researchers. Lal-Nag joined NCATS’ Division of Pre-Clinical Innovation in 2013, where she worked as a research scientist in biology with Marc Ferrer, Ph.D., primarily to develop an assay platform of three-dimensional (3-D) physiologically relevant, multi-cell-type disease models that are amenable to high-throughput screening. Lal-Nag received a Ph.D. in molecular and cellular oncology from George Washington University, where she worked with Steven R. Patierno, Ph.D., and Susan Ceryak, Ph.D., to uncover mechanisms of oncogenic cell signaling under conditions of genotoxic stress. As a postdoctoral fellow in the laboratory of Patrice Morin, Ph.D., Lal-Nag worked on developing conjugated enterotoxins for treating high-grade serous ovarian carcinoma.

Research Topics

Lal-Nag’s core competency lies in being able to bridge the gap between the academic and the translational aspects of cutting edge science, and in using the results of current chemotherapeutic response/regimens to dictate the direction of research for maximum effectiveness in as short a time as possible. Her passion lies in being able to develop scientific methods to creatively translate cutting-edge research to serve patient needs. Lal-Nag has extensive experience in the miniaturization and optimization of physiologically relevant cell-based 2-D and 3-D assays to make them amenable for the screening of high-impact, small molecule and functional genomics libraries with the goal of identifying unique receptor/ligand interaction and efficacy in various disease pathologies, especially as they relate to the epigenetic modulation of cancer and stem cell biology.

Selected Publications

  1. Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells.
  2. PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.
  3. A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth.
  4. Triad of human cellular proteins, IRF2, FAM111A, and RFC3, restrict replication of orthopoxvirus SPI-1 host-range mutants.
  5. Exploring Drug Dosing Regimens In Vitro Using Real-Time 3D Spheroid Tumor Growth Assays.